CClinicalTrials.gg
CompletedNCT05244590Updated Feb 14, 2023

Primary Care Consultation for Patients With Palliative Care Needs

An interventional study of Consultation model for patients with palliative care needs in Palliative Care and Primary Health Care, sponsored by University of Coimbra. Completed at 1 site in Portugal. Per ClinicalTrials.gov, last updated 2023-02-14.

Sponsored by University of Coimbra · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Sex
All
01

Study summary

Introduction General practitioners provide health care in the community, managing patients and families longitudinally, and there is some evidence that when they are involved in caring for people with palliative care needs alongside specialists, palliative care delivery may be more efficient. The investigators aim to determine the impact of a mix-method intervention involving training in PC and a new consultation model for patients with palliative care needs in primary care.

Methods and analysis A before-after study will be conducted in the centre health care region of Portugal. The study will involve 53 patients with palliative care needs from the list of patients of the GPs who accept to collaborate with the project. The mix-method intervention will consist of: (1) training in palliative care and (2) application of a newly developed consultation model for use in the primary care setting and consisting of medical consultation every 3 weeks for a period of 12 weeks. The primary outcome is physical symptom burden, evaluated by the Integrated Palliative Outcome Scale (IPOS) patient version. Secondary outcomes include psychological symptoms, and communication/practical issues (IPOS); number of consultations for acute disease both in the health care unit and emergency department, number of hospitalizations and referrals to hospital health care services.

Read the detailed description

Study aim:

The investigators aim to develop, apply, and evaluate a mix-method intervention involving training in PC and a new consultation model in primary care for patients with PC needs.

Primary objective:

To determine the impact of the intervention on the physical symptom burden for patients.

Secondary objectives:

To determine the impact of the intervention on:

  1. psychological symptoms burden.
  2. communication/practical issues.
  3. some determinants of health care service use (number of consultations for acute disease both in the health care unit and emergency department, number of hospitalizations and referrals to hospital health care services).

Study design:

Before-after study

Study procedures:

GPs working in the centre health care region in Portugal will be asked to collaborate with the project.

GPs will receive a training program on PC built based on our previous study with GPs where the investigators identified the role of GPs in the PC setting and their training needs in PC. They will also receive training on how to apply the new consultation model.

Each GP will be asked to recruit patients with PC needs from their own list of patients using a protocol developed for that purpose. Each patient recruited will receive a medical consultation every 3 weeks for a period of 12 weeks. In both the first and last medical consultations, each GP will ask patients to complete the Integrated Palliative Outcome Scale (IPOS) patient version.

The study will integrate a pilot evaluation involving the first two patients of each GP, so that the consultation model can be improved according to the collected feedback.

The investigators intend to assess whether our mix-method intervention can improve the physical symptom burden of patients with PC needs after a 12-week intervention

Sample size:

Sample size was calculated for the main outcome (physical symptom burden) measured using the IPOS, considering the two time points (baseline and 12 weeks after). The effect of the intervention will be measured by the difference between the two means tested using t-test for paired samples, A sample size of 53 patients is estimated, considering a power of 80%, a type I error of 5%, and a medium effect size of 0.513, and accommodating a 50% loss of patients at follow-up (UCSF Clinical \& Translational Science Institute - Sample Size Calculators, available at http://www.sample-size.net). Given that the prevalence of patients with PC needs in primary care is 8% to 14%3,4 and that in Portugal each GP has, on average, 1600 to 1900 patients in their list, it is estimated that each GP will have around 128 patients with PC needs in their list. Considering the involvement of 8-10 GPs in the study, the planned sample size is feasible. Included GPs will be asked to recruit patients until the planned sample size is reached (around 6 patients per GP).

Data collection:

The following variables will be collected by the main researcher about the GPs participating in the study: age, sex, years of clinical practice, type of primary care unit in which they work, environment (rural or urban) and previous training in PC.

The following variables will be collected by each GP about the patients participating in the study using a paper form: age, sex, education, marital status, rural or urban environment, main diagnosis, and comorbidities and IPOS patient version scores. GPs will also collect, by searching patients' medical records: number of consultations for acute disease both in the health care unit and emergency department, number of hospitalizations and referrals to hospital health care services referring to 12-week pre intervention and 12-week post intervention. A 12-week timeframe for evaluating resource use before and after the intervention was chosen to assess how these variables behaved over a period equal to that of the intervention. Each form will be pseudo-anonymized by assigning a code, so that only each GP will be able to identify which patient each form belongs to.

Statistical analysis:

Data analysis will be performed using SPSS v. 27®. Categorical variables will be described by frequencies (absolutes and relatives). Normally distributed continuous variables will be summarized by mean and standard deviation. Ordinal and non-normally distributed continuous variables will be represented by median and interquartile interval. The normality of the distributions will be assessed by observation of the respective QQ-plots.

To compare the difference of the two moments (baseline and 12 weeks after) a t-test for paired samples or a Wilcoxon test will be used. Statistical significance will be set at p\<0.05.

02

Conditions studied

  • Palliative Care
  • Primary Health Care
03

In context

Lead sponsor

University of Coimbra is the lead sponsor of 84 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

GPs' eligibility criteria Inclusion criteria

  • Working in the centre health care region in Portugal.
  • Authorisation of the coordinator of each GP health care unit to integrate the study.

Patients' eligibility criteria Inclusion criteria

  • Belonging to the list of patients of the recruited GPs.
  • 18 years or older.
  • Diagnosis of advanced stage neoplasm (ASN), Chronic Obstructive Pulmonary Disease (COPD) Gold III/IV, Congestive Heart Failure (CHF) NYHA III/IV, Chronic Kidney Disease (CKD) stage IV/V.

Exclusion Criteria

  • Refusal, at any time, to participate in the study.
  • Level of understanding or execution that compromises taking part in the study and answering the IPOS patient version (evaluated using Mini Mental State Examination score).
  • Level of disease severity requiring urgent intervention (GP clinical judgement).
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Intervention

    GPs' eligibility criteria * Working in the centre health care region in Portugal. * Authorisation of the coordinator of each GP health care unit to integrate the study. Patients' eligibility criteria Inclusion criteria * Belonging to the list of patients of the recruited GPs. * 18 years or older. * Diagnosis of advanced stage neoplasm (ASN), Chronic Obstructive Pulmonary Disease (COPD) Gold III/IV, Congestive Heart Failure (CHF) NYHA III/IV, Chronic Kidney Disease (CKD) stage IV/V. Exclusion Criteria * Refusal, at any time, to participate in the study. * Level of understanding or execution that compromises taking part in the study and answering the IPOS patient version (evaluated using Mini Mental State Examination score). * Level of disease severity requiring urgent intervention (GP clinical judgement).

    Other: Consultation model for patients with palliative care needs

Interventions

  • OtherConsultation model for patients with palliative care needs

    Training in PC for GPs The training program for GPs will meet the main training needs of GPs according to our previous study and feedback from elements of the Palliative Care Study Group of the Portuguese Association of General and Family Medicine (GESPal). The training program will have a total duration of 24 hours and will consist of two modules. Consultation model for patients Consultations will take place every 3 weeks for a total period of 12 weeks. The consultation model will be divided into five areas (Summarize clinical information, Objective symptoms' management, Assessment and coding of chronic diseases and symptoms, planning clinical approach, (other) problems/concerns) to be addressed during the assessment. The five areas were constructed to be intuitive for GPs, following the records' structure used in Portuguese primary care.

06

What researchers measure

Primary outcomes

  1. Impact of the intervention in patients' physical symptom burden evaluated using Integrated Palliative Outcome Scale (IPOS) - patient version's mean scores

    GPs enrolled will evaluate physical symptoms burden before and after the 12 week intervention.

    Time frame: 12 week

Secondary outcomes

  1. Impact of the intervention in patients' psychological symptoms burden evaluated using Integrated Palliative Outcome Scale (IPOS) - patient version's mean scores

    GPs enrolled will evaluate psychological symptoms burden before and after the 12 week intervention.

    Time frame: 12 week

  2. Impact of the intervention in patients' communication/practical issues evaluated using Integrated Palliative Outcome Scale (IPOS) - patient version's mean scores

    GPs enrolled will evaluate communication/practical issues before and after the 12 week intervention.

    Time frame: 12 week

  3. Impact of the intervention on number of consultations for acute disease both in the health care unit and emergency department, number of hospitalizations and referrals to hospital health care services

    GPs enrolled will evaluate this variables 3 month before and 3 month after the 12 week intervention.

    Time frame: 12 week

07

Study locations

1 site
  • ARS Centro
    Coimbra, 3000, Portugal
08

References and documents

Individual participant data

Plan to share: Yes — Results will be published in peer-reviewed journals and presented at national and international conferences.

Supporting information: Study protocol, Sap, Csr

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05244590
Lead sponsor
University of Coimbra
Responsible party
Carlos Seiça Cardoso (Primary investigator, University of Coimbra) — Principal investigator
First posted
Feb 17, 2022
Start date
Apr 27, 2022
Primary completion
Jan 1, 2023
Completion
Feb 3, 2023
Last update
Feb 14, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion